Standard Operating Procedure for Country Filing Sequence Planning
| Department | Regulatory Affairs |
| SOP No. | RA/2026/661 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 10/04/2026 |
| Effective Date | 10/04/2026 |
| Review Date | 10/04/2028 |
Purpose
This Standard Operating Procedure (SOP) establishes a standardized approach for planning and managing the sequence of country-specific regulatory filings for pharmaceutical products. It aims to ensure timely, compliant, and coordinated submissions aligned with business priorities, regulatory requirements, and market entry strategies. This SOP supports effective management control over submission timelines, resource allocation, and cross-functional communication, facilitating compliance with applicable global and local regulations.
Scope
This SOP applies to all activities involved in planning, sequencing, and scheduling regulatory filings for product registrations, variations, renewals, and related documentation across all countries in which the company operates or intends to market pharmaceutical products. It encompasses interactions between regulatory affairs, quality assurance, manufacturing, legal, and commercial functions. The SOP excludes actual dossier preparation, submission, or post-submission follow-up processes covered by separate procedural documents.
Responsibilities
Regulatory Affairs Team: Develop, update, and maintain the country filing sequence plan; coordinate with internal and external stakeholders.
Regulatory Strategy Managers: Provide input on regulatory timelines and priorities.
Quality Assurance: Review plans for compliance aspects and ensure documentation control.
Project Managers: Facilitate cross-functional coordination and monitor progress.
Senior Management: Provide oversight on strategic decisions affecting filing sequence.
Documentation Control: Manage versioning and archival of sequence planning records.
Accountability
The Head of Regulatory Affairs holds overall accountability for the implementation, ongoing compliance, periodic review, escalation of issues, and effectiveness of this SOP. This role ensures the filing sequence plan supports regulatory and business objectives while meeting all regulatory obligations.
Procedure
1. Preparation and Prerequisites:
a) Gather comprehensive product data, approved dossiers, and prior regulatory submissions.
b) Collect current country-specific regulatory requirements, timelines, and guidelines from authoritative sources.
c) Assess business priorities, market opportunities, and resource availability.
d) Engage relevant internal departments and external partners to obtain input and confirm constraints.
2. Sequence Planning and Strategy:
a) List all countries targeted for filing with corresponding submission types and deadlines.
b) Evaluate and rank countries based on strategic importance, regulatory risk, and complexity.
c) Identify dependencies such as reference country approvals, local clinical data needs, or manufacturing site readiness.
d) Develop an initial filing schedule with tentative submission dates aligned to regulatory timelines and internal capacity.
e) Incorporate contingency plans for potential delays or changes in regulatory environment.
3. Review and Validation:
a) Share proposed country filing sequence plan with cross-functional stakeholders for review.
b) Address feedback, revise schedules as needed, and obtain formal approval from the Head of Regulatory Affairs.
c) Validate that the plan complies with all regulatory requirements and business objectives.
d) Finalize documentation and control versions per document management procedures.
4. Execution and Monitoring:
a) Disseminate approved sequence plan to all involved functions, ensuring clarity on roles and timelines.
b) Periodically monitor progress against planned submission dates using status reports and key performance indicators.
c) Identify deviations or emerging risks early, initiate corrective actions, and document changes.
d) Update the sequence plan as necessary, with approval and version control maintained.
e) Maintain records of filing sequences, approvals, revisions, and correspondence for regulatory inspection readiness.
5. Closure and Continuous Improvement:
a) Upon completion of filing activities, document outcomes, lessons learned, and process efficiencies.
b) Review the SOP and filing sequence plan periodically as per scheduled review dates or when regulatory changes occur.
c) Incorporate improvements identified through audits, inspections, or internal feedback.
d) Ensure training on updated procedures is provided to relevant personnel.
This compliant and comprehensive procedure ensures a streamlined and documented approach to managing country-specific filing sequences, fostering regulatory compliance and strategic market entry success within a controlled pharmaceutical environment.
Abbreviations
RA – Regulatory Affairs
SOP – Standard Operating Procedure
GMP – Good Manufacturing Practice
QA – Quality Assurance
PM – Project Manager
CTA – Clinical Trial Application
Documents
- Country Filing Sequence Plan Template (Annexure-1)
- Regulatory Requirements Checklist per Country (Annexure-2)
- Filing Sequence Change Request Form (Annexure-3)
References
ICH Q12 – Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
EMA and FDA Guidelines on Regulatory Submissions
ICH Q7 – Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
Internal Quality Management System Documentation Control Procedure
Regional Regulatory Authority Requirements Documentation
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Country Filing Sequence Plan Template
Purpose: To document and track the planned sequence of regulatory submissions across countries.
| Country | Submission Type | Planned Submission Date | Regulatory Authority | Reference Country | Status | Remarks |
|---|---|---|---|---|---|---|
| Country A | New Drug Application | 15/06/2026 | Authority A | Country X | Planned | Priority market |
| Country B | Variation Application | 30/07/2026 | Authority B | Country A | Planned | Dependent on approval in Country A |
| Country C | Renewal | 10/12/2026 | Authority C | NA | Planned | Annual renewal |
Annexure-2: Regulatory Requirements Checklist per Country
Purpose: Checklist to verify key regulatory requirements for each intended filing country.
| Country | CTD Format | Local Regulatory Fee | Language Requirements | Local Agent Required | Additional Data Required | Submission Timeline |
|---|---|---|---|---|---|---|
| Country A | eCTD | Applicable | English | Yes | Stability data | 90 days |
| Country B | Paper & eCTD | Applicable | French | No | Bioequivalence study | 120 days |
| Country C | eCTD | Not Applicable | English/Local language | Yes | Pharmacovigilance plan | 60 days |
Annexure-3: Filing Sequence Change Request Form
Purpose: To formally request, document, and approve changes to the approved country filing sequence plan.
| Request No. | FSC-2026-001 |
| Date of Request | 01/05/2026 |
| Proposed Change | Move filing date for Country B from 30/07/2026 to 30/09/2026 |
| Reason for Change | Delay in receiving local clinical data |
| Impact Assessment | Potential delay in market entry by two months; update resource allocation accordingly |
| Requested By | Regulatory Strategy Team |
| Reviewed By | Quality Assurance |
| Approval Status | Pending |
| Approved By | |
| Date of Approval |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 10/04/2026 | 1.0 | Initial issue | New SOP creation |